The clearance is supported by data from the PRESERVE trial (NCT04972097), which evaluated the safety and effectiveness of the NanoKnife System in ablating prostate tissue in patients with intermediate ...

A new study has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought.

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...

Netanyahu underwent surgery after he was diagnosed with an infection stemming from a benign enlargement of his prostate, according to media reports.

Discover the study supports the potential of neoadjuvant androgen deprivation therapy as an adjunctive therapy in HRLPC.

The study found that Focal One's treatment methods match up with the gold star standard of surgery, and improve quality of life outcomes.

Dec. 18, 2024 — Research has uncovered a vulnerability in prostate cancer animal models that starves prostate tumors of critical nutrients and stunts their growth, which could lead to the ...

Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel ...

Future Oncol. 2009;5(7):923-926. What is the definition of early-onset prostate cancer? How can genetic polymorphisms predict who is at risk of developing prostate cancer at a young age?

A new global prostate cancer awareness campaign developed by biopharmaceutical companies AstraZeneca (AZ) and Merck & Co. (MSD) has just been launched in the US and Canada: ‘Never Miss ...

As temperatures drop, a trend of increased prostate-related problems among men over 60 is concerning and requires immediate attention. Benign prostatic hyperplasia (BPH), also known as an enlarged ...

Here the authors report the results of a phase 1 trial of PSCA-directed autologous CAR-T cells with pharmacological activation by rimiducid in patients with metastatic pancreatic or prostate cancer.